Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
2018 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
Ludolph, A. C; Schuster, J.; Dorst, J.; Dupuis, L.; Dreyhaupt, J.; Weishaupt, J. H & Kassubek, J. et al. (2018)
The Lancet Neurology, 17(8) pp. 681-688. DOI: https://doi.org/10.1016/S1474-4422(18)30176-5
